Results 191 to 200 of about 36,108 (238)

Downstream Pathways of Dystrophin Deficiency in Duchenne Muscular Dystrophy: Implications for Muscle Degeneration and Regeneration

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Background Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy, primarily affecting skeletal muscle and leading to premature death. Although the loss of dystrophin has long been recognised as the primary cause of the disease, no definitive cure is currently available. As a consequence, therapeutic efforts
Raffaele Epis, Gabriele Rovetta, Giulia Ferrari, Chiara Bonfanti, Giorgia Careccia, Graziella Messina   +5 more
wiley   +1 more source

RRAEDy: adaptive latent linearization of nonlinear dynamical systems. [PDF]

Sci Rep
Mounayer J, Rodriguez S, Tomezyk J, Ghnatios C, Chinesta F.   +4 more
europepmc   +1 more source

Supercritical Angle Fluorescence and Raman Techniques in Biophotonics

Laser &Photonics Reviews, Volume 20, Issue 15, 7 August 2026.
Supercritical angle fluorescence (SAF) microscopy and supercritical angle Raman (SAR) spectroscopy have emerged as powerful tools in the field of biophotonics, enabling high‐resolution imaging and spectroscopy of biological specimens near interfaces. This review article provides a comprehensive overview of the principles, techniques, applications, and ...
Subir Das, Nathalia Simea Münch, Stefan Seeger   +2 more
wiley   +1 more source

A novel spatiotemporal decomposition and identification of sparse equations for human brain deformation. [PDF]

Sci Rep
Arani AHG, Alshareef AA, Pham DL, Okamoto RJ, Bayly PV.   +4 more
europepmc   +1 more source

The Economic Burden of Duchenne Muscular Dystrophy: A Systematic Review. [PDF]

Pharmacoeconomics
Landfeldt E, Åberg M, Bello L, Deroo V, Born AP, Giusti S, Ekström AB.   +6 more
europepmc   +1 more source

Five‐Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study

Muscle &Nerve, Volume 74, Issue 2, Page 397-403, August 2026.
ABSTRACT Aims We report 5‐year results from a phase 1/2a study of delandistrogene moxeparvovec, a recombinant adeno‐associated virus serotype rh74 vector‐based gene therapy for Duchenne muscular dystrophy (DMD), with post hoc analyses contextualizing functional outcomes. Methods Four ambulatory patients with DMD (≥ 4–< 8 years at enrollment) entered an
Jerry R. Mendell, Zarife Sahenk, Linda P. Lowes, Megan A. Iammarino, Lindsay N. Alfano, Craig M. McDonald, James E. Signorovitch, Jim Jin, Jing Li, Stefanie Mason, Louise R. Rodino‐Klapac   +10 more
wiley   +1 more source

Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment. [PDF]

Cell Death Dis
Fernández-Simón E, Tejedera-Villafranca A, Fernández-Garabay X, Clark J, Katsikis P, Mehra P, Galloway A, Monceau A, Villalobos E, Cox D, Ramón-Azcón J, Fernández-Costa JM, Díaz-Manera J.   +12 more
europepmc   +1 more source

Emerging roles of microRNAs and other non-coding transcriptome in muscular dystrophies. [PDF]

Inflamm Regen
Abdelrehim FG, Sadek Z, Fahim SA, El-Ekiaby N, Abdelaziz AI, Fawzy IO.   +5 more
europepmc   +1 more source

Creatine/Creatinine Ratio and Myostatin as Biomarkers to Monitor Muscle Function in Duchenne Muscular Dystrophy Patients. [PDF]

J Cachexia Sarcopenia Muscle
Degan C, Tsonaka R, de Vries SI, Ikelaar NA, van der Holst M, Kan HE, Niks EH, Spitali P.   +7 more
europepmc   +1 more source

RNA Therapeutics for Duchenne Muscular Dystrophy: Exon Skipping, RNA Editing, and Translational Insights from Genome-Edited Microminipig Models. [PDF]

Int J Mol Sci
Chassin A, Ono H, Ashida Y, Imamura M, Aoki Y.   +4 more
europepmc   +1 more source